文献速递肿瘤 PET/CT甲状腺核医学

18F-FDG PET/CT检出局灶性甲状腺摄取进展为弥漫性摄取:恶性转移性疾病还是良性甲状腺炎?

Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT: Malignant Metastatic Disease or Benign Thyroiditis?
PubMed 文献 · Clin Nucl Med · 2018-01-01

一例49岁男性因不明原发灶脑转移行18F-FDG PET/CT评估,检出疑似肺原发癌及偶发左甲状腺局灶性摄取;1个月后超声显示甲状腺炎表现,2个月后确诊肺腺癌并拟行抗PD1免疫治疗;第二次基线FDG PET/CT显示甲状腺弥漫性摄取,甲状腺实质细针穿刺活检最终证实为肺腺癌弥漫性累及(即原发性肺癌甲状腺转移)。

要点

  • FDG PET/CT偶发局灶性甲状腺摄取可进展为弥漫性摄取,需警惕恶性转移可能。
  • 超声提示甲状腺炎表现后,后续FDG PET/CT出现弥漫性甲状腺摄取。
  • 甲状腺细针穿刺活检证实为肺腺癌甲状腺弥漫性转移。

核心结论

  • FDG PET/CT检出的局灶性甲状腺摄取进展为弥漫性摄取,最终经细针穿刺活检证实为肺腺癌甲状腺转移。

研究设计与样本

  • 一例49岁男性病例报告,因不明原发灶脑转移行18F-FDG PET/CT评估。

主要发现

  • 首次18F-FDG PET/CT检出疑似肺原发癌及偶发左甲状腺局灶性摄取。
  • 1个月后超声显示甲状腺炎表现,2个月后确诊肺腺癌并拟行抗PD1免疫治疗。
  • 第二次基线FDG PET/CT显示甲状腺弥漫性摄取。
  • 甲状腺实质细针穿刺活检证实为肺腺癌弥漫性累及(原发性肺癌甲状腺转移)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 49-year-old man was referred to our department for an assessment of a cerebral metastasis of unknown primary with F-FDG PET/CT. This imaging led to detection of a suspected pulmonary primary carcinoma, as well as an incidental left focal thyroid uptake. An ultrasonography, performed a month later, revealed a thyroiditis aspect. An anti-PD1 immunotherapy was also proposed 2 months later after confirmation of a lung adenocarcinoma. A second baseline FDG PET/CT surprisingly showed a diffuse thyroid uptake. A fine-needle aspiration biopsy of thyroid parenchyma finally revealed a diffuse involvement from lung adenocarcinoma (ie, primary lung metastasis to the thyroid gland).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thuillier P, Crouzeix G, Descourt R, et al. Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT: Malignant Metastatic Disease or Benign Thyroiditis? Clin Nucl Med. 2018. PMID: 29939952. doi:10.1097/RLU.0000000000002168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。